Breast cancer (HER2 positive, unresectable) - trastuzumab emtansine (after trastuzumab & taxane) [ID603]

Anticipated publication date:

Trastuzumab emtansine for treating unresectable metastatic HER2-positive breast cancer after treatment with trastuzumab and a taxane
 
Status
In development
Anticipated publication date
TBC
Process
STA
Topic area
  • Cancer

Provisional Schedule

Closing date for invited submissions / evidence submission: 10 December 2013
1st appraisal committee meeting: 25 March 2014
2nd appraisal committee meeting TBC

Project Team

Associate Director: Frances Sutcliffe
Technical Lead: Ahmed Elsada
Communications manager: Laura Gibson
Project manager:

Bijal Joshi

Technical Advisor: Sally Doss

Timeline

Key events during the development of the guidance

Date
Update
Dates
Notes
23 May 2014
The Committee discussion for trastuzumab emtansine for treating HER2-positive, locally advanced or metastatic breast cancer that was due to take place on 28 May 2014 has been cancelled. This is due to the consideration of a commercial arrangement proposed by the manufacturer.
Get involved